Use of the Dietary Supplements NR and NMN to Increase Nicotinamide Adenine Dinucleotide, Impact Mitochondrial Function, and Improve Metabolic Health
Abstract
1. Introduction
2. Role of NAD+ in Cellular Metabolic Processes
3. Nicotinamide Riboside (NR)
3.1. Animal Studies of NR
3.2. Human Studies of NR
4. Nicotinamide Mononucleotide (NMN)
4.1. NMN Transport into Cells
4.2. Animal Studies of NMN
4.3. Human Studies of NMN
5. Practical Applications and Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
| Aβ | Amyloid-beta |
| AKT | Protein kinase B |
| BACE-1 | Beta-secretase 1 |
| CK-MB | Creatine kinase MB |
| DNA | Deoxyribonucleic acid |
| eNAMPT | Extracellular nicotinamide phosphoribosyltransferase |
| HMGB1 | High Mobility Group Box 1 |
| HOMA | Homeostatic Model Assessment |
| LDH | Lactate dehydrogenase |
| mTOR | Mechanistic target of rapamycin |
| NAD+ | Nicotinamide adenine dinucleotide |
| NaMN | Nicotinic acid mononucleotide |
| NMN | Nicotinamide mononucleotide |
| NR | Nicotinamide riboside |
| SIRT5 | Sirtuin 5 |
References
- Rajman, L.; Chwalek, K.; Sinclair, D.A. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell Metab. 2018, 27, 529–547. [Google Scholar] [CrossRef] [PubMed]
- Gindri, I.D.M.; Ferrari, G.; Pinto, L.P.S.; Bicca, J.; Dos Santos, I.K.; Dallacosta, D.; Roesler, C.R.D.M. Evaluation of Safety and Effectiveness of NAD in Different Clinical Conditions: A Systematic Review. Am. J. Physiol.-Endocrinol. Metab. 2024, 326, E417–E427. [Google Scholar] [CrossRef]
- Goody, M.F.; Henry, C.A. A Need for NAD+ in Muscle Development, Homeostasis, and Aging. Skelet. Muscle 2018, 8, 9. [Google Scholar] [CrossRef]
- Imai, S. NAD World 3.0: The Importance of the NMN Transporter and eNAMPT in Mammalian Aging and Longevity Control. npj Aging 2025, 11, 4. [Google Scholar] [CrossRef] [PubMed]
- Massudi, H.; Grant, R.; Braidy, N.; Guest, J.; Farnsworth, B.; Guillemin, G.J. Age-Associated Changes in Oxidative Stress and NAD+ Metabolism in Human Tissue. PLoS ONE 2012, 7, e42357. [Google Scholar] [CrossRef]
- Prolla, T.A.; Denu, J.M. NAD+ Deficiency in Age-Related Mitochondrial Dysfunction. Cell Metab. 2014, 19, 178–180. [Google Scholar] [CrossRef]
- Gomes, A.P.; Price, N.L.; Ling, A.J.Y.; Moslehi, J.J.; Montgomery, M.K.; Rajman, L.; White, J.P.; Teodoro, J.S.; Wrann, C.D.; Hubbard, B.P.; et al. Declining NAD+ Induces a Pseudohypoxic State Disrupting Nuclear-Mitochondrial Communication during Aging. Cell 2013, 155, 1624–1638. [Google Scholar] [CrossRef] [PubMed]
- Zapata-Pérez, R.; Wanders, R.J.A.; Van Karnebeek, C.D.M.; Houtkooper, R.H. NAD+ Homeostasis in Human Health and Disease. EMBO Mol. Med. 2021, 13, e13943. [Google Scholar] [CrossRef]
- Campbell, J.M. Supplementation with NAD+ and Its Precursors to Prevent Cognitive Decline across Disease Contexts. Nutrients 2022, 14, 3231. [Google Scholar] [CrossRef]
- Bogan, K.L.; Brenner, C. Nicotinic Acid, Nicotinamide, and Nicotinamide Riboside: A Molecular Evaluation of NAD+ Precursor Vitamins in Human Nutrition. Annu. Rev. Nutr. 2008, 28, 115–130. [Google Scholar] [CrossRef]
- Yoshino, J.; Baur, J.A.; Imai, S. NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR. Cell Metab. 2018, 27, 513–528. [Google Scholar] [CrossRef]
- Alegre, G.F.S.; Pastore, G.M. NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health. Curr. Nutr. Rep. 2023, 12, 445–464. [Google Scholar] [CrossRef]
- Abdellatif, M.; Sedej, S.; Kroemer, G. NAD+ Metabolism in Cardiac Health, Aging, and Disease. Circulation 2021, 144, 1795–1817. [Google Scholar] [CrossRef]
- Yusri, K.; Jose, S.; Vermeulen, K.S.; Tan, T.C.M.; Sorrentino, V. The Role of NAD+ Metabolism and Its Modulation of Mitochondria in Aging and Disease. npj Metab. Health Dis. 2025, 3, 26. [Google Scholar] [CrossRef]
- Fang, J.; Chen, W.; Hou, P.; Liu, Z.; Zuo, M.; Liu, S.; Feng, C.; Han, Y.; Li, P.; Shi, Y.; et al. NAD+ Metabolism-Based Immunoregulation and Therapeutic Potential. Cell Biosci. 2023, 13, 81. [Google Scholar] [CrossRef]
- Houtkooper, R.H.; Pirinen, E.; Auwerx, J. Sirtuins as Regulators of Metabolism and Healthspan. Nat. Rev. Mol. Cell Biol. 2012, 13, 225–238. [Google Scholar] [CrossRef] [PubMed]
- Mehmel, M.; Jovanović, N.; Spitz, U. Nicotinamide Riboside—The Current State of Research and Therapeutic Uses. Nutrients 2020, 12, 1616. [Google Scholar] [CrossRef] [PubMed]
- Imai, S.; Guarente, L. NAD+ and Sirtuins in Aging and Disease. Trends Cell Biol. 2014, 24, 464–471. [Google Scholar] [CrossRef]
- Biţă, A.; Scorei, I.R.; Ciocîlteu, M.V.; Nicolaescu, O.E.; Pîrvu, A.S.; Bejenaru, L.E.; Rău, G.; Bejenaru, C.; Radu, A.; Neamţu, J.; et al. Nicotinamide Riboside, a Promising Vitamin B3 Derivative for Healthy Aging and Longevity: Current Research and Perspectives. Molecules 2023, 28, 6078. [Google Scholar] [CrossRef] [PubMed]
- Braidy, N.; Liu, Y. Can Nicotinamide Riboside Protect against Cognitive Impairment? Curr. Opin. Clin. Nutr. Metab. Care 2020, 23, 413–420. [Google Scholar] [CrossRef]
- Wu, J.; Han, K.; Sack, M.N. Targeting NAD+ Metabolism to Modulate Autoimmunity and Inflammation. J. Immunol. 2024, 212, 1043–1050. [Google Scholar] [CrossRef]
- Schaefer, P.M.; Huang, J.; Butic, A.; Perry, C.; Yardeni, T.; Tan, W.; Morrow, R.; Baur, J.A.; Wallace, D.C. Nicotinamide Riboside Alleviates Exercise Intolerance in ANT1-Deficient Mice. Mol. Metab. 2022, 64, 101560. [Google Scholar] [CrossRef]
- Diguet, N.; Trammell, S.A.J.; Tannous, C.; Deloux, R.; Piquereau, J.; Mougenot, N.; Gouge, A.; Gressette, M.; Manoury, B.; Blanc, J.; et al. Nicotinamide Riboside Preserves Cardiac Function in a Mouse Model of Dilated Cardiomyopathy. Circulation 2018, 137, 2256–2273. [Google Scholar] [CrossRef]
- Cantó, C.; Houtkooper, R.H.; Pirinen, E.; Youn, D.Y.; Oosterveer, M.H.; Cen, Y.; Fernandez-Marcos, P.J.; Yamamoto, H.; Andreux, P.A.; Cettour-Rose, P.; et al. The NAD+ Precursor Nicotinamide Riboside Enhances Oxidative Metabolism and Protects against High-Fat Diet-Induced Obesity. Cell Metab. 2012, 15, 838–847. [Google Scholar] [CrossRef]
- Curry, A.M.; Rymarchyk, S.; Herrington, N.B.; Donu, D.; Kellogg, G.E.; Cen, Y. Nicotinamide Riboside Activates SIRT5 Deacetylation. FEBS J. 2023, 290, 4762–4776. [Google Scholar] [CrossRef]
- Trammell, S.A.J.; Schmidt, M.S.; Weidemann, B.J.; Redpath, P.; Jaksch, F.; Dellinger, R.W.; Li, Z.; Abel, E.D.; Migaud, M.E.; Brenner, C. Nicotinamide Riboside Is Uniquely and Orally Bioavailable in Mice and Humans. Nat. Commun. 2016, 7, 12948. [Google Scholar] [CrossRef]
- Zhao, K.; Tang, J.; Xie, H.; Liu, L.; Qin, Q.; Sun, B.; Qin, Z.; Sheng, R.; Zhu, J. Nicotinamide Riboside Attenuates Myocardial Ischemia-Reperfusion Injury via Regulating SIRT3/SOD2 Signaling Pathway. Biomed. Pharmacother. 2024, 175, 116689. [Google Scholar] [CrossRef]
- Dierickx, P.; Carpenter, B.J.; Celwyn, I.; Kelly, D.P.; Baur, J.A.; Lazar, M.A. Nicotinamide Riboside Improves Cardiac Function and Prolongs Survival After Disruption of the Cardiomyocyte Clock. Front. Mol. Med. 2022, 2, 887733. [Google Scholar] [CrossRef] [PubMed]
- Hong, G.; Zheng, D.; Zhang, L.; Ni, R.; Wang, G.; Fan, G.-C.; Lu, Z.; Peng, T. Administration of Nicotinamide Riboside Prevents Oxidative Stress and Organ Injury in Sepsis. Free Radic. Biol. Med. 2018, 123, 125–137. [Google Scholar] [CrossRef] [PubMed]
- Podyacheva, E.; Semenova, N.; Zinserling, V.; Mukhametdinova, D.; Goncharova, I.; Zelinskaya, I.; Sviridov, E.; Martynov, M.; Osipova, S.; Toropova, Y. Intravenous Nicotinamide Riboside Administration Has a Cardioprotective Effect in Chronic Doxorubicin-Induced Cardiomyopathy. Int. J. Mol. Sci. 2022, 23, 13096. [Google Scholar] [CrossRef] [PubMed]
- Kourtzidis, I.A.; Stoupas, A.T.; Gioris, I.S.; Veskoukis, A.S.; Margaritelis, N.V.; Tsantarliotou, M.; Taitzoglou, I.; Vrabas, I.S.; Paschalis, V.; Kyparos, A.; et al. The NAD+ Precursor Nicotinamide Riboside Decreases Exercise Performance in Rats. J. Int. Soc. Sports Nutr. 2016, 13, 32. [Google Scholar] [CrossRef]
- Damgaard, M.V.; Treebak, J.T. What Is Really Known about the Effects of Nicotinamide Riboside Supplementation in Humans. Sci. Adv. 2023, 9, eadi4862. [Google Scholar] [CrossRef]
- Airhart, S.E.; Shireman, L.M.; Risler, L.J.; Anderson, G.D.; Nagana Gowda, G.A.; Raftery, D.; Tian, R.; Shen, D.D.; O’Brien, K.D. An Open-Label, Non-Randomized Study of the Pharmacokinetics of the Nutritional Supplement Nicotinamide Riboside (NR) and Its Effects on Blood NAD+ Levels in Healthy Volunteers. PLoS ONE 2017, 12, e0186459. [Google Scholar] [CrossRef] [PubMed]
- Conze, D.; Brenner, C.; Kruger, C.L. Safety and Metabolism of Long-Term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Healthy Overweight Adults. Sci. Rep. 2019, 9, 9772. [Google Scholar] [CrossRef] [PubMed]
- Dellinger, R.W.; Santos, S.R.; Morris, M.; Evans, M.; Alminana, D.; Guarente, L.; Marcotulli, E. Repeat Dose NRPT (Nicotinamide Riboside and Pterostilbene) Increases NAD+ Levels in Humans Safely and Sustainably: A Randomized, Double-Blind, Placebo-Controlled Study. npj Aging Mech. Dis. 2017, 3, 17. [Google Scholar] [CrossRef]
- Wang, D.D.; Airhart, S.E.; Zhou, B.; Shireman, L.M.; Jiang, S.; Melendez Rodriguez, C.; Kirkpatrick, J.N.; Shen, D.D.; Tian, R.; O’Brien, K.D. Safety and Tolerability of Nicotinamide Riboside in Heart Failure with Reduced Ejection Fraction. JACC Basic Transl. Sci. 2022, 7, 1183–1196. [Google Scholar] [CrossRef]
- Lapatto, H.A.K.; Kuusela, M.; Heikkinen, A.; Muniandy, M.; Van Der Kolk, B.W.; Gopalakrishnan, S.; Pöllänen, N.; Sandvik, M.; Schmidt, M.S.; Heinonen, S.; et al. Nicotinamide Riboside Improves Muscle Mitochondrial Biogenesis, Satellite Cell Differentiation, and Gut Microbiota in a Twin Study. Sci. Adv. 2023, 9, eadd5163. [Google Scholar] [CrossRef]
- Dollerup, O.L.; Chubanava, S.; Agerholm, M.; Søndergård, S.D.; Altıntaş, A.; Møller, A.B.; Høyer, K.F.; Ringgaard, S.; Stødkilde-Jørgensen, H.; Lavery, G.G.; et al. Nicotinamide Riboside Does Not Alter Mitochondrial Respiration, Content or Morphology in Skeletal Muscle from Obese and Insulin-resistant Men. J. Physiol. 2020, 598, 731–754. [Google Scholar] [CrossRef] [PubMed]
- Stocks, B.; Ashcroft, S.P.; Joanisse, S.; Dansereau, L.C.; Koay, Y.C.; Elhassan, Y.S.; Lavery, G.G.; Quek, L.; O’Sullivan, J.F.; Philp, A.M.; et al. Nicotinamide Riboside Supplementation Does Not Alter Whole-body or Skeletal Muscle Metabolic Responses to a Single Bout of Endurance Exercise. J. Physiol. 2021, 599, 1513–1531. [Google Scholar] [CrossRef]
- McDermott, M.M.; Martens, C.R.; Domanchuk, K.J.; Zhang, D.; Peek, C.B.; Criqui, M.H.; Ferrucci, L.; Greenland, P.; Guralnik, J.M.; Ho, K.J.; et al. Publisher Correction: Nicotinamide Riboside for Peripheral Artery Disease: The NICE Randomized Clinical Trial. Nat. Commun. 2024, 15, 6890. [Google Scholar] [CrossRef]
- Dolopikou, C.F.; Kourtzidis, I.A.; Margaritelis, N.V.; Vrabas, I.S.; Koidou, I.; Kyparos, A.; Theodorou, A.A.; Paschalis, V.; Nikolaidis, M.G. Acute Nicotinamide Riboside Supplementation Improves Redox Homeostasis and Exercise Performance in Old Individuals: A Double-Blind Cross-over Study. Eur. J. Nutr. 2020, 59, 505–515. [Google Scholar] [CrossRef]
- Custodero, C.; Saini, S.K.; Shin, M.J.; Jeon, Y.K.; Christou, D.D.; McDermott, M.M.; Leeuwenburgh, C.; Anton, S.D.; Mankowski, R.T. Nicotinamide Riboside—A Missing Piece in the Puzzle of Exercise Therapy for Older Adults? Exp. Gerontol. 2020, 137, 110972. [Google Scholar] [CrossRef] [PubMed]
- Prokopidis, K.; Moriarty, F.; Bahat, G.; McLean, J.; Church, D.D.; Patel, H.P. The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis. J. Cachexia Sarcopenia Muscle 2025, 16, e13799. [Google Scholar] [CrossRef]
- Campelj, D.; Philp, A. NAD+ Therapeutics and Skeletal Muscle Adaptation to Exercise in Humans. Sports Med. 2022, 52, 91–99. [Google Scholar] [CrossRef]
- Ferreira, L.S.S.; De-Souza, E.A. Of Mice and Men: Opposing Effects of Nicotinamide Riboside on Skeletal Muscle Physiology at Rest and during Exercise. J. Physiol. 2021, 599, 2525–2526. [Google Scholar] [CrossRef]
- Yamaguchi, S.; Irie, J.; Mitsuishi, M.; Uchino, Y.; Nakaya, H.; Takemura, R.; Inagaki, E.; Kosugi, S.; Okano, H.; Yasui, M.; et al. Safety and Efficacy of Long-Term Nicotinamide Mononucleotide Supplementation on Metabolism, Sleep, and Nicotinamide Adenine Dinucleotide Biosynthesis in Healthy, Middle-Aged Japanese Men. Endocr. J. 2024, 71, 153–169. [Google Scholar] [CrossRef]
- Song, Q.; Zhou, X.; Xu, K.; Liu, S.; Zhu, X.; Yang, J. The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: An Update. Adv. Nutr. 2023, 14, 1416–1435. [Google Scholar] [CrossRef] [PubMed]
- Poddar, S.K.; Sifat, A.E.; Haque, S.; Nahid, N.A.; Chowdhury, S.; Mehedi, I. Nicotinamide Mononucleotide: Exploration of Diverse Therapeutic Applications of a Potential Molecule. Biomolecules 2019, 9, 34. [Google Scholar] [CrossRef] [PubMed]
- Igarashi, M.; Nakagawa-Nagahama, Y.; Miura, M.; Kashiwabara, K.; Yaku, K.; Sawada, M.; Sekine, R.; Fukamizu, Y.; Sato, T.; Sakurai, T.; et al. Chronic Nicotinamide Mononucleotide Supplementation Elevates Blood Nicotinamide Adenine Dinucleotide Levels and Alters Muscle Function in Healthy Older Men. npj Aging 2022, 8, 5. [Google Scholar] [CrossRef]
- Ramanathan, C.; Lackie, T.; Williams, D.H.; Simone, P.S.; Zhang, Y.; Bloomer, R.J. Oral Administration of Nicotinamide Mononucleotide Increases Nicotinamide Adenine Dinucleotide Level in an Animal Brain. Nutrients 2022, 14, 300. [Google Scholar] [CrossRef]
- Yi, L.; Maier, A.B.; Tao, R.; Lin, Z.; Vaidya, A.; Pendse, S.; Thasma, S.; Andhalkar, N.; Avhad, G.; Kumbhar, V. The Efficacy and Safety of β-Nicotinamide Mononucleotide (NMN) Supplementation in Healthy Middle-Aged Adults: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Dependent Clinical Trial. GeroScience 2023, 45, 29–43. [Google Scholar] [CrossRef] [PubMed]
- Okabe, K.; Yaku, K.; Tobe, K.; Nakagawa, T. Implications of Altered NAD Metabolism in Metabolic Disorders. J. Biomed. Sci. 2019, 26, 34. [Google Scholar] [CrossRef]
- Soma, M.; Lalam, S.K. The Role of Nicotinamide Mononucleotide (NMN) in Anti-Aging, Longevity, and Its Potential for Treating Chronic Conditions. Mol. Biol. Rep. 2022, 49, 9737–9748. [Google Scholar] [CrossRef]
- Deng, H.; Ding, D.; Ma, Y.; Zhang, H.; Wang, N.; Zhang, C.; Yang, G. Nicotinamide Mononucleotide: Research Process in Cardiovascular Diseases. Int. J. Mol. Sci. 2024, 25, 9526. [Google Scholar] [CrossRef]
- Liao, B.; Zhao, Y.; Wang, D.; Zhang, X.; Hao, X.; Hu, M. Nicotinamide Mononucleotide Supplementation Enhances Aerobic Capacity in Amateur Runners: A Randomized, Double-Blind Study. J. Int. Soc. Sports Nutr. 2021, 18, 54. [Google Scholar] [CrossRef]
- Grozio, A.; Mills, K.F.; Yoshino, J.; Bruzzone, S.; Sociali, G.; Tokizane, K.; Lei, H.C.; Cunningham, R.; Sasaki, Y.; Migaud, M.E.; et al. Slc12a8 Is a Nicotinamide Mononucleotide Transporter. Nat. Metab. 2019, 1, 47–57. [Google Scholar] [CrossRef]
- Mills, K.F.; Yoshida, S.; Stein, L.R.; Grozio, A.; Kubota, S.; Sasaki, Y.; Redpath, P.; Migaud, M.E.; Apte, R.S.; Uchida, K.; et al. Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice. Cell Metab. 2016, 24, 795–806. [Google Scholar] [CrossRef] [PubMed]
- Zhou, A.; Xiong, Z.; Wang, L.; Chen, X.; Wang, Z.; Zhang, Y.; Chen, W.; Cai, X.; Xu, Y.; Rong, S.; et al. Long-Term Administration of Nicotinamide Mononucleotide Mitigates High-Fat-Diet-Induced Physiological Decline in Aging Mice. J. Nutr. 2025, 155, 237–249. [Google Scholar] [CrossRef]
- Wang, L.; Chen, Y.; Wei, J.; Guo, F.; Li, L.; Han, Z.; Wang, Z.; Zhu, H.; Zhang, X.; Li, Z.; et al. Administration of Nicotinamide Mononucleotide Improves Oocyte Quality of Obese Mice. Cell Prolif. 2022, 55, e13303. [Google Scholar] [CrossRef]
- Ru, M.; Wang, W.; Zhai, Z.; Wang, R.; Li, Y.; Liang, J.; Kothari, D.; Niu, K.; Wu, X. Nicotinamide Mononucleotide Supplementation Protects the Intestinal Function in Aging Mice and d-Galactose Induced Senescent Cells. Food Funct. 2022, 13, 7507–7519. [Google Scholar] [CrossRef] [PubMed]
- Li, H.; Liu, Q.; Zhu, C.; Sun, X.; Sun, C.; Yu, C.; Li, P.; Deng, X.; Wang, J. β-Nicotinamide Mononucleotide Activates NAD+/SIRT1 Pathway and Attenuates Inflammatory and Oxidative Responses in the Hippocampus Regions of Septic Mice. Redox Biol. 2023, 63, 102745. [Google Scholar] [CrossRef] [PubMed]
- Irie, J.; Inagaki, E.; Fujita, M.; Nakaya, H.; Mitsuishi, M.; Yamaguchi, S.; Yamashita, K.; Shigaki, S.; Ono, T.; Yukioka, H.; et al. Effect of Oral Administration of Nicotinamide Mononucleotide on Clinical Parameters and Nicotinamide Metabolite Levels in Healthy Japanese Men. Endocr. J. 2020, 67, 153–160. [Google Scholar] [CrossRef]
- Yoshino, M.; Yoshino, J.; Kayser, B.D.; Patti, G.J.; Franczyk, M.P.; Mills, K.F.; Sindelar, M.; Pietka, T.; Patterson, B.W.; Imai, S.-I.; et al. Nicotinamide Mononucleotide Increases Muscle Insulin Sensitivity in Prediabetic Women. Science 2021, 372, 1224–1229. [Google Scholar] [CrossRef] [PubMed]
- Kim, M.; Seol, J.; Sato, T.; Fukamizu, Y.; Sakurai, T.; Okura, T. Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese Adults: A Randomized, Double-Blind Placebo-Controlled Study. Nutrients 2022, 14, 755. [Google Scholar] [CrossRef]
- Huang, H. A Multicentre, Randomised, Double Blind, Parallel Design, Placebo Controlled Study to Evaluate the Efficacy and Safety of Uthever (NMN Supplement), an Orally Administered Supplementation in Middle Aged and Older Adults. Front. Aging 2022, 3, 851698. [Google Scholar] [CrossRef]
- Katayoshi, T.; Uehata, S.; Nakashima, N.; Nakajo, T.; Kitajima, N.; Kageyama, M.; Tsuji-Naito, K. Nicotinamide Adenine Dinucleotide Metabolism and Arterial Stiffness after Long-Term Nicotinamide Mononucleotide Supplementation: A Randomized, Double-Blind, Placebo-Controlled Trial. Sci. Rep. 2023, 13, 2786. [Google Scholar] [CrossRef] [PubMed]


Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bloomer, R.J.; Timmcke, J.Q.; Ramanathan, C. Use of the Dietary Supplements NR and NMN to Increase Nicotinamide Adenine Dinucleotide, Impact Mitochondrial Function, and Improve Metabolic Health. Clin. Bioenerg. 2025, 1, 9. https://doi.org/10.3390/clinbioenerg1020009
Bloomer RJ, Timmcke JQ, Ramanathan C. Use of the Dietary Supplements NR and NMN to Increase Nicotinamide Adenine Dinucleotide, Impact Mitochondrial Function, and Improve Metabolic Health. Clinical Bioenergetics. 2025; 1(2):9. https://doi.org/10.3390/clinbioenerg1020009
Chicago/Turabian StyleBloomer, Richard J., Judi Quilici Timmcke, and Chidambaram Ramanathan. 2025. "Use of the Dietary Supplements NR and NMN to Increase Nicotinamide Adenine Dinucleotide, Impact Mitochondrial Function, and Improve Metabolic Health" Clinical Bioenergetics 1, no. 2: 9. https://doi.org/10.3390/clinbioenerg1020009
APA StyleBloomer, R. J., Timmcke, J. Q., & Ramanathan, C. (2025). Use of the Dietary Supplements NR and NMN to Increase Nicotinamide Adenine Dinucleotide, Impact Mitochondrial Function, and Improve Metabolic Health. Clinical Bioenergetics, 1(2), 9. https://doi.org/10.3390/clinbioenerg1020009

